 Compass Pathways NASDAQ:CMPS, a biotech company in the psychedelics space, announced it has completed a key milestone on its path to obtaining FDA approval for psilocybin in the treatment of depression. The company reported that it had completed psilocybin administration to all 216 patients that were targeted for Compass phase IIb clinical trial for treatment-resistant depression. 